Evaluation of Clinical Significance of Lymphovascular Space Invasion in Stage IA Endometrial Cancer
Evaluation of Clinical Significance of Lymphovascular Space Invasion in Stage IA Endometrial Cancer
复制标题
DOI：
10.1159/000521382
复制
发表时间：
2022-04-01
期刊：
影响因子：
3.5
通讯作者：
Kato, Kiyoko
中科院分区：
文献类型：
--
作者：
Okugawa, Kaoru;Yahata, Hideaki;Kato, Kiyoko
导言：淋巴血管间隙浸润（LVSI）在IA期子宫内膜癌的预后意义尚不清楚。本研究的目的是评价LVSI在IA期子宫内膜癌中的临床意义。方法：回顾性分析2008年1月至2018年12月在我院接受初次手术的IA期子宫内膜癌患者的临床资料。从医疗记录和病理报告中获得患者、手术和肿瘤特征的信息。结果：297例患者入组本研究。中位随访60个月，15例复发（5.1%），4例死于子宫内膜癌（1.3%）。lvsi阳性组和阴性组的复发率和死亡率无显著差异（p = 0.07和p = 0.41）。两组患者的无复发生存率和子宫内膜癌特异性生存率也无显著差异（p = 0.11和p = 0.49）。伴有和不伴有LVSI的子宫内膜癌5年特异性生存率分别为97.0%和98.9%。在低级别肿瘤患者中，有无LVSI的肿瘤患者的无复发生存率和子宫内膜癌特异性生存率无显著差异（p = 0.92和p = 0.72）。低级别肿瘤伴和不伴LVSI的5年子宫内膜癌特异性生存率分别为100%和99.3%。结论：LVSI不仅不是IA期子宫内膜癌的预后因素，也不是IA期低分级子宫内膜癌的预后因素。
Introduction: The prognostic significance of lymphovascular space invasion (LVSI) in stage IA endometrial cancer remains unclear. The aim of this study was to evaluate the clinical significance of LVSI in stage IA endometrial cancer. Methods: Clinical data of patients with stage IA endometrial cancer who underwent initial surgery at our institution between January 2008 and December 2018 were reviewed retrospectively. Information of patients, surgery, and characteristics of cancer were obtained from medical records and pathological reports. Results: Two hundred ninety-seven patients were enrolled in this study. With a median follow-up of 60 months, 15 patients experienced recurrence (5.1%) and 4 patients died of endometrial cancer (1.3%). The recurrence and mortality rates did not differ significantly between the LVSI-positive and -negative groups (p = 0.07 and p = 0.41, respectively). Recurrence-free survival and endometrial cancer-specific survival also did not differ significantly between these groups (p = 0.11 and p = 0.49, respectively). The 5-year endometrial cancer-specific survival rates for tumors with and without LVSI were 97.0% and 98.9%, respectively. Among patients with low-grade tumors, recurrence-free survival and endometrial cancer-specific survival did not differ significantly between patients with tumors with and without LVSI (p = 0.92 and p = 0.72, respectively). The 5-year endometrial cancer-specific survival rates for low-grade tumors with and without LVSI were 100% and 99.3%, respectively. Conclusion: LVSI was not a prognostic factor of not only stage IA endometrial cancer but also stage IA low-grade cancer.